Advertisement

Acta Diabetologica

, Volume 51, Issue 6, pp 1073–1075 | Cite as

Successful desensitization in patient with type 2 diabetes with an insulin allergy using insulin pump and glargine

  • G. PetrovskiEmail author
  • M. Zivkovic
  • T. Milenkovic
  • I. Ahmeti
  • I. Bitovska
Case Report

Introduction

Insulin allergy is rare, but they can occur in patients starting insulin therapy. There are different insulin desensitization protocols where insulin is diluted and given to the patient in small doses for a period of couple of days.

We report the case of patient with type 2 diabetes with insulin allergy, where desensitization was performed using insulin pump (Medtronic Minimed Veo) with glargine.

Case presentation

A 59-year-old man with type 2 diabetes was referred to our clinic by a diabetologist. Asymptomatic type 2 diabetes was diagnosed before 9 years with glycemia 12.5 mmol/l, HbA1c 8.6 % (70 mmol/mol) and BMI 29.4 kg/m2. Diet, physical exercise and metformin (1,000 mg) were prescribed and satisfactory glucose control (HbA1c around 7 % (70 mmol/mol)) was maintained in the next 4 years. Over the last 4 years, due to deterioration of diabetes (HbA1crising from 7.2 to 8.5 % (55–69 mmol/mol)), glimepiride (53 increasing to 4 mg) was introduced together with metformin...

Keywords

Metformin Pioglitazone Insulin Glargine Cetirizine Insulin Analogue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The study was performed with support of National Health Care Fund as regular billed services.

Conflict of interest

G. Petrovski, M. Zivkovic, T. Milenkovic, I. Ahmeti and I. Bitovska declare that they have no conflict of interest.

Human and Animal Rights disclosure

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

Informed consent disclosure

Informed consent was obtained from all patients for being included in the study.

References

  1. 1.
    Ghazavi MK, Johnston GA (2011) Insulin allergy. Clin Dermatol 29(3):300–305PubMedCrossRefGoogle Scholar
  2. 2.
    Sola-Gazagnes A, Pecquet C, Allergie à l’insuline en (2003) Journées de Diabétologie de l’Hôtel Dieu. Flammarion Médecine-Sciences 2004:161–179Google Scholar
  3. 3.
    Ping W, Cheng J, Mingli W et al (2013) Desensitization of allergy to human insulin and its analogs by administering insulin aspart and insulin glargine. Annales d’Endocrinologie 74:56–58Google Scholar
  4. 4.
    Thompson DM, Ronco JJ (1993) Prolonged desensitization required for treatment of generalized allergy to human insulin. Diabetes Care 16:957–958PubMedGoogle Scholar
  5. 5.
    Naf S, Esmatjes E, Recasens M, Valero A, Halperin I, Levy I, Gomis R (2002) Continuous subcutaneous insulin infusion to resolve an allergy to human insulin. Diabetes Care 25:634–635PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  • G. Petrovski
    • 1
    Email author
  • M. Zivkovic
    • 1
  • T. Milenkovic
    • 1
  • I. Ahmeti
    • 1
  • I. Bitovska
    • 1
  1. 1.Medical FacultyUniversity Clinic of Endocrinology, Diabetes and Metabolic DisordersSkopjeMacedonia

Personalised recommendations